Renaissance Technologies
KYTX icon

Renaissance Technologies’s Kyverna Therapeutics KYTX Stock Holding History

Renaissance Technologies’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.17M Buy
367,492
+189,593
+107% +$1.58M 0.01% 1636
2025
Q4 		$1.67M Buy
177,899
+13,285
+8% +$98.6K ﹤0.01% 1977
2025
Q3 		$988K Buy
164,614
+42,197
+34% +$169K ﹤0.01% 2489
2025
Q2 		$376K Sell
122,417
-2,541
-2% -$6.29K ﹤0.01% 2968
2025
Q1 		$241K Buy
124,958
+80,258
+180% +$237K ﹤0.01% 3009
2024
Q4 		$167K Buy
+44,700
New +$214K ﹤0.01% 3209

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Renaissance Technologies's KYTX Position: Q1 2026 in Review

Renaissance Technologies increased its Kyverna Therapeutics (KYTX) stake by 107% in Q1 2026, buying an estimated $1.58M and bringing the position to 367,492 shares worth $3.17M. The position accounts for 0.01% of the portfolio, ranked #1636.

Renaissance Technologies first reported a position in KYTX in Q4 2024 and has held it in 6 quarters since. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Renaissance Technologies held 367,492 shares of Kyverna Therapeutics worth $3.17M as of Q1 2026.
  • Renaissance Technologies bought 189,593 Kyverna Therapeutics shares in Q1 2026, an estimated $1.58M.
  • Kyverna Therapeutics made up 0.01% of Renaissance Technologies's portfolio in Q1 2026, its #1636 holding.
  • Renaissance Technologies first reported a position in Kyverna Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.